Evidence map›Paper›PMID 42424164›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Axial Coordination and Defect Engineering of Copper-Based Single-Atom Nanozymes: Driving Synergistic Disulfidptosis and Pyroptosis for Efficient Prostate Cancer Immunotherapy.

Bo Xu, Bin Wang, Wen Zhang, Bin Zhang, Xiaofeng Wang, Siqi Liu, Yinzhe Wang, Lianchao Yang, Rui Niu, Ying Tang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bo XuDepartment of Urology, The First Hospital of Jilin University, Changchun, Jilin, China.
Bin WangDepartment of Neurosurgery, The First Hospital of Jilin University, Changchun, Jilin, China.
Wen ZhangDepartment of Emergency, The First Hospital of Jilin University, Changchun, Jilin, China.
Bin ZhangKey Laboratory of Rare Earths, Chinese Academy of Sciences, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China.
Xiaofeng WangDepartment of Urology, The First Hospital of Jilin University, Changchun, Jilin, China.
Siqi LiuDepartment of Urology, The First Hospital of Jilin University, Changchun, Jilin, China.
Yinzhe WangDepartment of Urology, The First Hospital of Jilin University, Changchun, Jilin, China.
Lianchao YangDepartment of Urology, The First Hospital of Jilin University, Changchun, Jilin, China.
Rui NiuKey Laboratory of Rare Earths, Chinese Academy of Sciences, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China.
Ying TangDepartment of Gastroenterology, The First Hospital of Jilin University, Changchun, Jilin, China.ORCID 0000-0002-1105-9003
Chunxi WangDepartment of Urology, The First Hospital of Jilin University, Changchun, Jilin, China.
Yinghui WangKey Laboratory of Rare Earths, Chinese Academy of Sciences, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China.ORCID 0000-0001-7305-5852

Funding

Basic Science Center Project of the National Natural Science Foundation of China 22388101doctor of excellence program (DEP), The First Hospital of Jilin University JDYY-DEP-2024054Jilin Province Natural Science Foundation YDZJ202601ZYTS648National Natural Science Foundation of China 22393932National Natural Science Foundation of China 52272169National Natural Science Foundation of China 52402352National Natural Science Foundation of China U23A20581Science and Technology Research Project of Education Department of Jilin Province JJKH20250167KJYouth Innovation Promotion Association of Chinese Academy of Sciences Y2023067
6 · The paper itself

Abstract

Immunotherapy for prostate cancer is severely restricted by the immunosuppressive tumor microenvironment (TME) and the intrinsic antioxidant defense systems of tumor cells. To address these challenges, we develop an efficient copper-based single-atom nanozyme platform (CuN

Indexed as

Antineoplastic AgentsCopperImmunotherapyProstatic NeoplasmsPyroptosisDisulfidptosisHumansMaleAntineoplastic AgentsCopperantitumor immunotherapyaxial coordinationdefect engineeringpyroptosissingle‐atom nanozymes

Identifiers

PMID42424164
PMCPMC13549029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.